News and Trends 26 Jan 2016
Gilead On Board, But Still No Easy Sailing for Galapagos with Phase IIa Failure
Galapagos (Belgium) and Gilead (US) announced today the closing and entry into force of their global license and collaboration agreement on filgotinib, just as results are released for a phase II trial against Ulcerative colitis. Under the terms of the agreement, the closing of this transaction triggers an upfront license fee payment of $300M by Gilead […]